Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management Seeking Alpha Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management. Vertex (VRTX) 2 months
Vertex Pharmaceuticals Incorporated (VRTX): Why Do Hedge Funds Recommend This Biotech Stock? Insider Monkey 2 weeks
Vertex Pharmaceuticals, Inc. (VRTX) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript) Seeking Alpha 2 weeks
Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I’m Not Convinced Seeking Alpha 2 weeks
Vertex, Inc.: Growth Momentum Continues With FCF Conversion Rates Inflecting Upwards Seeking Alpha 4 weeks
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second. The Motley Fool 2 months
Vertex Slumps As Guidance Hike — Featuring The Gene-Editing Launch — Fails To Erase Losses Investor's Business Daily 2 months
Vertex sues US over fertility support program for Casgevy gene editing therapy Investing.com 2 months
Prediction: This Will Be Vertex Pharmaceuticals’ New Billion-Dollar Growth Driver (and It’s Coming Soon). The Motley Fool 2 months
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 The Motley Fool 3 months
Google to shore up Vertex AI’s enterprise credentials with addition of Mistral Small, Large and Codestral models VentureBeat 3 months
Vertex Pharmaceutical Incorporated. (VRTX): Analysts are Bullish on this Healthcare Stock’s Strong Financial Performance in Q1 Insider Monkey 3 months